Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. |
| |
| Authors: | A H Banham M Colonna M Cella K J Micklem K Pulford A C Willis D Y Mason |
| |
| Affiliation: | University of Oxford, Nuffield Department of Clinical Biochemistry and Cellular Science, John Radcliffe Hospital, Headington, United Kingdom. abanham@worf.molbiol.ox.ac.uk |
| |
| Abstract: | The CD85 molecule was originally defined at the Fifth Workshop on Leucocyte Antigens in 1993 by two monoclonal antibodies, VMP55 and GHI/75. This cell-surface glycoprotein is expressed on B cells, monocytes, and subpopulations of T and natural killer (NK) cells, and particularly high levels are expressed by normal and neoplastic plasma cells and by hairy cell leukemia B cells. We affinity purified the CD85 antigen and obtained tryptic peptide sequence which indicated that this molecule might be ILT2, a recently described inhibitory major histocompatibility complex class I receptor of the immunoglobulin superfamily. This was confirmed by showing that both of the original anti-CD85 mAbs stained ILT2 transfectants. The cell signaling role demonstrated for ILT2 is consistent with the previously reported involvement of CD85 in T cell activation. |
| |
| Keywords: | |
|
|
